Fig. 3From: CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrestSHR6390 induced cell cycle arrest at G1 phase in Eca 109 and KYSE-510 cell lines. a Flow cytometric analysis showed that the percentage of cells accumulated in G1 phase significantly increased after treatment with SHR6390 alone compared to the control in Eca 109 and KYSE-510 cell lines not in Eca 9706 cell line. b The expressions of p53 and p21 was further upregulated by SHR6390 concomitant with cell cycle arrest at G1 phase. The data are expressed as the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by one-way ANOVA or unpaired two-tailed t testBack to article page